Design Therapeutics, Inc. Operating Cash Flow
Design Therapeutics, Inc. (DSGN) reported Operating Cash Flow of -$31.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.52M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$16.43M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.97M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$11.16M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$54.36M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$43.10M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$58.56M.
- Design Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$51.32M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$31.95M 10-Q · filed 2026-08-03 | -$43.92M derived: sum of 3 quarters · filed 2026-08-03 | -$55.08M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$16.43M 10-Q · filed 2026-04-28 | -$28.40M derived: sum of 2 quarters · filed 2026-04-28 | -$39.56M derived: sum of 3 quarters · filed 2026-04-28 | -$54.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$11.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$23.13M derived: sum of 2 quarters · filed 2026-03-09 | -$37.57M derived: sum of 3 quarters · filed 2026-08-03 | -$54.36M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$11.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$25.60M derived: sum of 2 quarters · filed 2026-08-03 | -$42.39M 10-Q · filed 2025-11-05 | -$52.25M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$14.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$31.23M 10-Q · filed 2026-08-03 | -$41.09M derived: sum of 3 quarters · filed 2026-08-03 | -$50.64M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$16.79M 10-Q · filed 2026-04-28 | -$26.65M derived: sum of 2 quarters · filed 2026-04-28 | -$36.20M derived: sum of 3 quarters · filed 2026-04-28 | -$47.45M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$9.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$19.41M derived: sum of 2 quarters · filed 2026-03-09 | -$30.67M derived: sum of 3 quarters · filed 2026-03-09 | -$43.10M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$9.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$20.81M derived: sum of 2 quarters · filed 2025-11-05 | -$33.24M 10-Q · filed 2025-11-05 | -$46.04M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$11.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$23.70M 10-Q · filed 2025-08-07 | -$36.50M derived: sum of 3 quarters · filed 2025-08-07 | -$51.03M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$12.44M 10-Q · filed 2025-05-07 | -$25.24M derived: sum of 2 quarters · filed 2025-05-07 | -$39.77M derived: sum of 3 quarters · filed 2025-05-07 | -$53.58M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$12.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$27.33M derived: sum of 2 quarters · filed 2025-03-10 | -$41.14M derived: sum of 3 quarters · filed 2025-03-10 | -$58.56M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$14.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$28.34M derived: sum of 2 quarters · filed 2024-11-07 | -$45.76M 10-Q · filed 2024-11-07 | -$60.85M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$13.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$31.23M 10-Q · filed 2024-08-05 | -$46.32M derived: sum of 3 quarters · filed 2024-08-05 | -$60.22M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$17.42M 10-Q · filed 2024-05-08 | -$32.52M derived: sum of 2 quarters · filed 2024-05-08 | -$46.41M derived: sum of 3 quarters · filed 2024-05-08 | -$56.91M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$28.99M derived: sum of 2 quarters · filed 2024-03-19 | -$39.49M derived: sum of 3 quarters · filed 2024-03-19 | -$51.32M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$13.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$24.40M derived: sum of 2 quarters · filed 2023-11-13 | -$36.23M 10-Q · filed 2023-11-13 | -$45.45M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$10.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$22.33M 10-Q · filed 2023-08-14 | -$31.55M derived: sum of 3 quarters · filed 2023-08-14 | -$39.72M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$11.83M 10-Q · filed 2023-05-09 | -$21.05M derived: sum of 2 quarters · filed 2023-05-09 | -$29.22M derived: sum of 3 quarters · filed 2023-05-09 | -$37.51M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$17.39M derived: sum of 2 quarters · filed 2023-03-14 | -$25.68M derived: sum of 3 quarters · filed 2023-03-14 | -$29.38M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$8.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$16.45M derived: sum of 2 quarters · filed 2022-11-03 | -$20.15M 10-Q · filed 2022-11-03 | -$22.99M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$8.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$11.99M 10-Q · filed 2022-08-08 | -$14.83M derived: sum of 3 quarters · filed 2022-08-08 | -$16.69M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$3.70M 10-Q · filed 2022-05-09 | -$6.54M derived: sum of 2 quarters · filed 2022-05-09 | -$8.40M derived: sum of 3 quarters · filed 2022-05-09 | -$9.71M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$4.70M derived: sum of 2 quarters · filed 2022-03-10 | -$6.01M derived: sum of 3 quarters · filed 2022-03-10 | -$8.67M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$3.17M derived: sum of 2 quarters · filed 2021-11-09 | -$5.83M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$3.97M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$2.66M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |